Exact Sciences shareholders approve $105 per share Abbott acquisition

Exact Sciences Corporation (NASDAQ: EXAS) announced that its stockholders voted to approve the proposed acquisition by Abbott (NYSE: ABT) at a special meeting held Thursday.

More than 99% of votes cast were in favor of the transaction, representing approximately 67% of total outstanding shares as of the January 9, 2026 record date. Final voting results will be reported in a Form 8-K filing with the Securities and Exchange Commission.

Under the definitive agreement terms, Exact Sciences stockholders will receive $105.00 in cash for each share upon completion of the transaction. The deal is expected to close before the end of the second quarter of 2026, subject to satisfaction of remaining closing conditions.

Exact Sciences provides cancer screening and diagnostic tests, including brands such as Cologuard and Oncotype DX. The Madison, Wisconsin-based company offers solutions for multi-cancer early detection and molecular residual disease monitoring.

The information is based on a press release statement from Exact Sciences.

You May Also Be Interested In

• Isabella Bank to acquire Grand River Commerce for $54.6 million
• Mistral AI in talks to raise funds at €20b valuation - Bloomberg
• Schwab reports record May activity with $49.9B in core net new assets